- Home
- PAYS vs EDIT Comparison
PAYS vs EDIT Comparison
Compare PAYS & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAYS | EDIT |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.6M | 432.8M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | PAYS | EDIT |
|---|---|---|
| Price | $8.68 | $2.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $9.42 | $5.30 |
| AVG Volume (30 Days) | 577.2K | ★ 2.4M |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.71 | 37.50 |
| EPS | ★ 0.09 | N/A |
| Revenue | $24,120,434.00 | ★ $31,937,000.00 |
| Revenue This Year | $33.83 | N/A |
| Revenue Next Year | $14.89 | N/A |
| P/E Ratio | $93.22 | ★ N/A |
| Revenue Growth | N/A | ★ 132.64 |
| 52 Week Low | $3.08 | $1.66 |
| 52 Week High | $9.30 | $4.54 |
Technical Indicators
Market Signals| Indicator | PAYS | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 57.60 | 37.19 |
| Support Level | $4.94 | $2.36 |
| Resistance Level | $9.30 | $2.73 |
| Average True Range (ATR) | 0.47 | 0.21 |
| MACD | -0.06 | -0.08 |
| Stochastic Oscillator | 50.91 | 2.06 |
Price Performance
Historical ComparisonAbout PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.